Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults

Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults

Objectives: T cell immunity is key for the control of viral infections including SARS-CoV-2, in particular with regard to immune memory and protection against arising genetic variants. Methods: We recently evaluated a peptide-based SARS-CoV-2 T cell activator termed CoVac-1 in a first-in-human trial...

Full description

Bibliographic Details
Main Authors: Claudia Tandler, Jonas S. Heitmann, Tanja M. Michel, Maddalena Marconato, Simon U. Jaeger, Christian M. Tegeler, Monika Denk, Marion Richter, Melek Tutku Oezbek, Yacine Maringer, Sarah M. Schroeder, Nicole Schneiderhan-Marra, Karl-Heinz Wiesmüller, Michael Bitzer, Natalia Ruetalo, Michael Schindler, Christoph Meisner, Imma Fischer, Hans-Georg Rammensee, Helmut R. Salih, Juliane S. Walz
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:International Journal of Infectious Diseases
Subjects:
SARS-CoV-2
Peptide
Vaccine
T cells
T cell immunity
B-cell deficiency
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971223007701

Internet

http://www.sciencedirect.com/science/article/pii/S1201971223007701

Similar Items